Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 2: Metastatic Disease — Thomas Powles, MBBS, MRCP, MD CME information and select publications

Urothelial Bladder Cancer | Thomas Powles, MBBS, MRCP, MD

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Medicine

Science & Medicine

Science

Health & Fitness

Featuring perspectives from Prof Nicoletta Colombo, Dr Matthew A Powell and Dr Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics:  Introduction (0:00) Current Approaches to First-Line Therapy for Advanced Endometrial Cancer (EC) — Prof Colombo (1:57) Novel Investigational Strategies for Newly Diagnosed EC — Dr Westin (25:35) Current Options for Relapsed/Refractory EC — Dr Slomovitz (45:57) Role of HER2-Targeted Therapy in the Management of Advanced EC — Dr Powell (1:05:54)  CME information and select publications

Endometrial Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Endometrial Cancer

Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics:  Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00) Biology and Current Clinical Management of PNH (36:35) Future Directions in PNH Management (55:34) Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26)  CME information and select publications

Paroxysmal Nocturnal Hemoglobinuria | Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria

Featuring an interview with Dr Emmanuel S Antonarakis, including the following topics:  Perspectives on advances in the management of prostate cancer over the last decade (0:00) Nonmetastatic high-risk prostate cancer and androgen deprivation therapy (ADT) intensification with abiraterone: Insights from the STAMPEDE trial (7:39) EMBARK: A Phase III trial of enzalutamide or placebo with leuprolide acetate and enzalutamide monotherapy for high-risk biochemically recurrent prostate cancer (15:25) Quality of life and preservation of sexual function with enzalutamide monotherapy compared to ADT alone or enzalutamide with ADT (20:20) Management of locally advanced prostate cancer with and without biochemical recurrence (23:58) PRESTO trial of ADT intensification with apalutamide with or without abiraterone for high-risk biochemically relapsed prostate cancer (30:35) CDK4/6 inhibitors, proteolysis-targeting chimeras and other novel therapeutic approaches for targeting androgen receptor signaling in prostate cancer (31:41) Choice of endocrine partner with ADT and incorporation of docetaxel in the treatment of metastatic hormone-sensitive prostate cancer (35:38) Other potential novel therapeutic strategies for prostate cancer (42:28) Integration of genomic testing for patients with prostate cancer; PARP inhibitor combinations for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (43:57) Incorporation of radiopharmaceuticals (ie, lutetium Lu 177 vipivotide tetraxetan, radium-223) into the management of prostate cancer (52:49) Perspectives on the results of the Phase III CONTACT-02 trial evaluating cabozantinib in combination with atezolizumab for mCRPC (57:44)  CME information and select publications  

Prostate Cancer | Oncology Today with Dr Neil Love: Special Edition – Prostate Cancer Updates from a CME Program Held at the 2024 Genitourinary Cancers Symposium

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:  Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00) Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35) Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21) Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10) Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33) Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38) Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08) Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56) Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48) Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18) Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)  CME information and select publications

Myeloproliferative Neoplasms | Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences

Featuring perspectives from Dr Andrew H Ko and Dr Eileen M O’Reilly, including the following topics.  Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Ko (0:00) Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr O’Reilly (31:46)  CME information and select publications

Urothelial Bladder Cancer | Thomas Powles, MBBS, MRCP, MD

Download our free app to listen on your phone